Latest news about Syncom Formulations
Syncom Formulations
17.56
+0.38(+2.21%)
Company Performance:
View Company Insights1D+2.21%
1M+34.15%
6M+36.97%
1Y+2.75%
5Y+116.79%
More news about Syncom Formulations
23May 26
Syncom FY26 Net Profit Rises 55.5% to ₹764.38 Crore
Syncom Formulations (India) Limited has submitted the press clipping for its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported a 55.5% increase in consolidated net profit to ₹764.38 crore for FY26, while Q4 net profit rose to ₹25.17 crore. Total income for the year grew to ₹5,205.11 crore, driven primarily by the Pharmaceuticals segment.
05May 26
Syncom Formulations (India) Limited Acquires Commercial Property from HDFC Bank Ltd for ₹57,26,00,000
Syncom Formulations (India) Limited disclosed on 4th May, 2026, the acquisition of the entire 7th Floor, Trade Star, Andheri-Kurla Road, Andheri (E), Mumbai-400059 from HDFC Bank Ltd. The total consideration paid for the property stands at ₹57,26,00,000 (Rupees Fifty-Seven Crore Twenty Six Lacs Only), representing full and final payment. The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015, and has been classified as a material development by the company.
07Apr 26
Syncom Formulations Confirms Non-Applicability of Large Corporate Criteria Under SEBI Regulations
Syncom Formulations (India) Limited confirmed to BSE and NSE on April 3, 2026, that it does not qualify as a "Large Corporate" under SEBI regulations. This status exempts the WHO-GMP and ISO certified pharmaceutical company from Annual Disclosure requirements in Annexure B2 for FY2025-26. The confirmation references multiple SEBI circulars including the primary regulation SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, and ensures compliance transparency with investors.
07Apr 26
Syncom Formulations Submits Q4FY26 Compliance Certificate Under SEBI Depositories Regulation
Syncom Formulations (India) Limited filed its Q4FY26 compliance certificate under SEBI Depositories Regulation 74(5) on April 7, 2026, covering the quarter ended March 31, 2026. The certificate, submitted by Company Secretary Vaishali Agrawal to BSE and NSE, confirms proper handling of dematerialization processes. Registrar Ankit Consultancy Pvt Ltd certified that all securities were appropriately processed, with physical certificates mutilated and depository names substituted in member registers within prescribed timeframes.
06Apr 26
Syncom Formulations Files Annual SEBI SAST Disclosure for FY26
Syncom Formulations (India) Limited filed its annual SEBI (SAST) disclosure for FY26 ended March 31, 2026, with promoters Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda declaring no new encumbrances on company securities. The regulatory filing was submitted to BSE and NSE on April 6, 2026, covering both promoters and their respective persons acting in concert groups.
03Apr 26
Syncom Formulations confirms non-applicability of SEBI Large Corporate criteria
Syncom Formulations (India) Limited confirmed to BSE and NSE on April 3, 2026, that it does not qualify as a "Large Corporate" under SEBI regulations. This classification exempts the WHO-GMP and ISO 9001-2000 certified pharmaceutical company from submitting Annual Disclosure requirements in Annexure B2 for the financial year ended March 31, 2026. The confirmation references multiple SEBI circulars and was digitally signed by Company Secretary Vaishali Agrawal for regulatory compliance and investor transparency.
04Feb 26
Syncom Formulations Board Meeting Scheduled for February 12, 2026 to Review Q3FY26 Financial Results
Syncom Formulations (India) Limited has scheduled its board meeting for February 12, 2026, at 3:00 PM to consider and approve standalone and consolidated unaudited financial results for Q3FY26 and nine months ended December 31, 2025. The meeting will be held at the company's corporate office in Indore, and the board will also review auditors' limited review reports and other incidental matters in compliance with SEBI regulations.
03Jan 26
Syncom Formulations Receives ₹1.42 Crore GST Demand Notice Including Penalty
Syncom Formulations has received a ₹1.42 crore GST demand notice including penalty for alleged ineligible input tax credits. The company plans to appeal the decision while maintaining regulatory compliance commitments.
22Nov 25
Syncom Formulations Acquires Mumbai Property for ₹51.70 Crore
Syncom Formulations (India) Limited has purchased a commercial property in Mumbai for ₹51.70 crore. The acquisition involves the entire 3rd floor of TradeStar building on Andheri-Kurla Road, sold by HDFC Bank Ltd. This transaction, considered material by the company, represents about 12.5% of Syncom's total assets based on FY 2025 figures. The strategic location in Andheri, a Mumbai business district, could provide operational advantages. This move may significantly impact the company's fixed asset base and indicates a commitment to long-term presence in Mumbai.
13Nov 25
Syncom Formulations Reports Mixed Q2 Performance with Revenue Decline and Profit Drop
Syncom Formulations (India) Limited's Q2 FY24 results show a decline in both revenue and profit compared to the previous quarter. Revenue decreased to ₹1,214.35 crore from ₹1,654.67 crore, while net profit dropped to ₹157.29 crore from ₹169.50 crore. The company's half-year revenue improved to ₹2,869.02 crore from ₹1,873.57 crore year-over-year. Basic EPS for the quarter was ₹0.18. Syncom operates in pharmaceuticals, commodity trading, and property renting segments.
18Aug 25
Syncom Formulations Announces Dual Leadership Resignations: CFO and Whole-time Director Step Down
Syncom Formulations (India) Limited reported the resignations of two senior executives. Shri Ankit Kedarmal Bankda stepped down as Chief Financial Officer, and Smt. Rinki Ankit Banka resigned as Director and Whole-time Director, both effective August 8, 2025. The company disclosed this information on August 18, 2025, citing internal processing and settlement formalities as reasons for the delayed announcement. The resignations were reported in compliance with SEBI regulations.
08Aug 25
Syncom Formulations Reports Strong Q1 Growth with Revenue Up 34% and Net Profit Doubling
Syncom Formulations (India) Limited reported impressive Q1 financial results. Revenue from operations increased by 34% to ₹11,654.69 crore, while net profit more than doubled to ₹1,572.93 crore, marking a 106% growth. EBITDA rose by 85% to ₹2,179.44 crore, with an improved EBITDA margin of 18.70%. The company's board announced several key appointments and leadership changes, including the re-designation of Shri Kedarmal Shankarlal Bankda and the appointment of Shri Ankit Kedarmal Bankda as Chairman and Whole Time Director. The 37th AGM is scheduled for September 29.
20May 25
Syncom Formulations Reports Impressive Q4 Results with Soaring Profits and Revenue
Syncom Formulations announced impressive Q4 financial results. Net profit soared 159.26% year-over-year to ₹175.00 crore, up 36.72% quarter-over-quarter. Revenue reached ₹1,500.00 crore, a 104.72% increase from the previous year. The company's strong performance indicates effective business strategies and high market demand for its products.
19May 25
Syncom Formulations Reports Impressive Q4 Financial Results with Substantial Growth
Syncom Formulations announced impressive Q4 financial results, with revenue soaring 104% year-over-year to ₹1,500.00 crore. Net profit surged 159% to ₹175.00 crore, while EBITDA nearly doubled to ₹175.00 crore. Despite strong overall performance, EBITDA margin slightly decreased to 11.67% from 12.02% in the previous year.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Laurus Labs
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
1,922.00
(+0.63%)
8,744.50
(+2.92%)
4,932.00
(+0.93%)
1,422.00
(-1.11%)
1,124.50
(+1.88%)
1,866.20
(+3.62%)
1,193.50
(+0.29%)
2,175.50
(-0.57%)
2,365.00
(-0.40%)
1,617.80
(+0.61%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
